CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net income (loss)	$ (194)	$ 884
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,875	1,680
Employee stock compensation expense	134	19
(Gain) on sale of property and equipment	0	(5)
Provision for doubtful accounts	(4)	0
Changes in operating assets and liabilities:
Accounts receivable	(589)	(941)
Inventories	(269)	540
Income taxes	(82)	7
Prepaid expenses and other assets	(77)	(14)
Accounts payable	980	(913)
Accrued expenses	103	113
Customer advances	1,610	(134)
Net cash provided by operating activities	3,487	1,236
Investing activities:
Cash paid in acquisition	(6,759)	0
Capital expenditures	(1,317)	(347)
Proceeds from sale of equipment	2	8
Net cash used in investing activities	(8,074)	(339)
Financing activities:
Payments of long-term debt	(331)	(3,721)
New borrowings on long-term debt	5,500	4,500
Payments of debt issuance costs	(113)	(214)
Proceeds from exercise of stock options	1	71
Payments on revolving line of credit	(7,545)	(11,516)
Borrowings on revolving line of credit	7,545	10,158
Payments on capital lease obligations	(131)	(127)
Net cash provided by (used in) financing activities	4,926	(849)
Net increase in cash and cash equivalents	339	48
Cash and cash equivalents at beginning of year	434	386
Cash and cash equivalents at end of year	773	434
Supplemental disclosure of cash flow information:
Cash paid for interest	233	230
Supplemental disclosure of non-cash financing activities:
Conversion of preferred shares to common shares	1,000	150
Seventh Wave Laboratories LLC acquisition:
Assets acquired	10,052	0
Liabilities assumed	(818)	0
Common shares issued	(2,475)	$ 0
Cash paid	$ 6,759